Literature DB >> 8527271

Pharmacokinetics of ketoprofen enantiomers after different doses of the racemate.

G Geisslinger1, S Menzel, K Wissel, K Brune.   

Abstract

The pharmacokinetics of the enantiomers of ketoprofen after oral administration of 12.5 mg, 25 mg and 50 mg and i.v. administration of 50 mg racemic ketoprofen to 24 healthy subjects were investigated. The AUC values of R- (r2 = 0.929) and S-ketoprofen (r2 = 0.930) were proportional to dose. The absolute bioavailability of the 50 mg oral dose was 84.5 (s.d. 20.6) % and 81.4 (18.0) % for R-ketoprofen and S-ketoprofen, respectively. With the exception of AUC values no dose dependent differences in pharmacokinetic parameters were observed. However, the R-enantiomer had higher AUC, lower clearance data and higher Cmax values than the S-form after oral administration. The results suggest that stereochemical and pharmacokinetic considerations cannot explain the lack of dose response observed with ketoprofen doses below 50 mg.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527271      PMCID: PMC1365030          DOI: 10.1111/j.1365-2125.1995.tb04537.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Stereoselective high-performance liquid chromatographic determination of ketoprofen, ibuprofen and fenoprofen in plasma using a chiral alpha 1-acid glycoprotein column.

Authors:  S Menzel-Soglowek; G Geisslinger; K Brune
Journal:  J Chromatogr       Date:  1990-11-16

2.  A double-blind, parallel comparison of ketoprofen, aspirin, and placebo in patients with postpartum pain.

Authors:  A Sunshine; I Zighelboim; E Laska; C Siegel; N Z Olson; A De Castro
Journal:  J Clin Pharmacol       Date:  1986 Nov-Dec       Impact factor: 3.126

3.  Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses.

Authors:  R T Foster; F Jamali; A S Russell; S R Alballa
Journal:  J Pharm Sci       Date:  1988-01       Impact factor: 3.534

4.  A double-blind parallel comparison of ketoprofen, codeine, and placebo in patients with moderate to severe postpartum pain.

Authors:  T Kantor; M B Cavaliere; M Hopper; S Roepke
Journal:  J Clin Pharmacol       Date:  1984 May-Jun       Impact factor: 3.126

Review 5.  Clinical pharmacokinetics of ketoprofen and its enantiomers.

Authors:  F Jamali; D R Brocks
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

6.  The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis.

Authors:  P J Hayball; R L Nation; F Bochner; L N Sansom; M J Ahern; M D Smith
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

7.  Pharmacokinetics of ketoprofen enantiomers in young and elderly arthritic patients following single and multiple doses.

Authors:  R T Foster; F Jamali; A S Russell; S R Alballa
Journal:  J Pharm Sci       Date:  1988-03       Impact factor: 3.534

8.  The disposition of ketoprofen enantiomers in man.

Authors:  B C Sallustio; Y J Purdie; A G Whitehead; M J Ahern; P J Meffin
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

9.  Double-blind parallel comparison of single oral doses of ketoprofen, codeine, and placebo in patients with moderate to severe dental pain.

Authors:  D Mehlisch; L Frakes; M B Cavaliere; M Gelman
Journal:  J Clin Pharmacol       Date:  1984 Nov-Dec       Impact factor: 3.126

  9 in total
  12 in total

1.  Comparison of tissue concentrations after intramuscular and topical administration of ketoprofen.

Authors:  I Tegeder; J Lötsch; M Kinzig-Schippers; F Sörgel; G R Kelm; S T Meller; G Geisslinger
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

2.  Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility, and dose-dependent BCS.

Authors:  Georgia Charkoftaki; Aristides Dokoumetzidis; Georgia Valsami; Panos Macheras
Journal:  Pharm Res       Date:  2012-07-04       Impact factor: 4.200

Review 3.  Biowaivers for oral immediate-release products: implications of linear pharmacokinetics.

Authors:  Fried Faassen; Herman Vromans
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Influence of Sex and Food on the Bioavailability and the R-to-S Conversion of Ketoprofen Stereoisomers in Humans.

Authors:  Pietro Fagiolino; Nikoletta Fotaki; Marta Vázquez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

5.  In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.

Authors:  Yasuhiro Tsume; Peter Langguth; Alfredo Garcia-Arieta; Gordon L Amidon
Journal:  Biopharm Drug Dispos       Date:  2012-08-21       Impact factor: 1.627

Review 6.  Preclinical and clinical development of dexketoprofen.

Authors:  D Mauleón; R Artigas; M L García; G Carganico
Journal:  Drugs       Date:  1996       Impact factor: 9.546

7.  Stereoselective Conversion of Ketoprofen in Men Versus Women from Two Different Oral Dosage Formulations: Observations and Introspection of the Pharmacokinetic Data.

Authors:  Ranjeet Prasad Dash; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

Review 8.  Clinical pharmacokinetics of dexketoprofen.

Authors:  M J Barbanoj; R M Antonijoan; I Gich
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

9.  The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.

Authors:  Yasuhiro Tsume; Deanna M Mudie; Peter Langguth; Greg E Amidon; Gordon L Amidon
Journal:  Eur J Pharm Sci       Date:  2014-01-28       Impact factor: 4.384

10.  Stereoselective Pharmacokinetics of Ketoprofen After Oral Administration of Modified-Release Formulations in Caucasian Healthy Subjects.

Authors:  Marianela Lorier; Laura Magallanes; Manuel Ibarra; Natalia Guevara; Marta Vázquez; Pietro Fagiolino
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.